Cargando…

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction

BACKGROUND: Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits in using Group 1 PH therapies in these patients, particularly in seve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinkamp, Colin A., Shah, Trushil, Bartolome, Sonja, Torres, Fernando, Chin, Kelly M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024797/ https://www.ncbi.nlm.nih.gov/pubmed/33841939 http://dx.doi.org/10.21037/jtd-20-1635

Ejemplares similares

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023)

Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing
por: Papa, Silvia, et al.
Publicado: (2023)

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine
por: Douwes, Johannes M., et al.
Publicado: (2022)

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy
por: Miles, Kimberley G., et al.
Publicado: (2023)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2022)

Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015)

BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series
por: Scelsi, Laura, et al.
Publicado: (2021)

Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension
por: Pan, Irene Z., et al.
Publicado: (2020)

Right Ventricular Dysfunction in Lupus Patients With Pulmonary Hypertension
por: Barberato, Silvio Henrique
Publicado: (2018)

How to Determine Right Ventricular Dysfunction in Pulmonary Hypertension
por: Kim, Hyung Yoon, et al.
Publicado: (2021)

Complex Role for E‐Prostanoid 4 Receptors in Hypertension
por: Herrera, Marcela, et al.
Publicado: (2019)

Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension
por: Maestas, Travis, et al.
Publicado: (2018)

Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020)

Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Thenappan, Thenappan, et al.
Publicado: (2021)

Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Caputo, Annalisa, et al.
Publicado: (2023)

Clinical study of right ventricular longitudinal strain for assessing right ventricular dysfunction and hemodynamics in pulmonary hypertension
por: Li, Yidan, et al.
Publicado: (2016)

Altered Prostanoid Metabolism Contributes to Impaired Angiogenesis in Persistent Pulmonary Hypertension of the Newborn
por: Mahajan, Chaitali N., et al.
Publicado: (2014)

Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

Lessons from the COMPASS-3 Study
por: Shah, Trushil, et al.
Publicado: (2018)

Right ventricular dysfunction and pulmonary hypertension: a neglected presentation of thyrotoxicosis
por: Singarayar, Carolina Shalini, et al.
Publicado: (2018)

Right Ventricular Dysfunction in Pulmonary Hypertension: Is Resistin a Promising Target?
por: Lemay, Sarah‐Eve, et al.
Publicado: (2023)

Predictors of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients with Hypersensitivity Pneumonitis
por: Trushenko, Natalia V., et al.
Publicado: (2023)

Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension
por: Yamagishi-Kimura, Reiko, et al.
Publicado: (2018)

Early Detection for Right Ventricular Dysfunction in Bronchopulmonary Dysplasia without Pulmonary Hypertension
por: Son, Jung-Woo
Publicado: (2016)

Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors
por: Rossi, Rosario, et al.
Publicado: (2022)

Prognostic role of pulmonary impedance estimation to predict right ventricular dysfunction in pulmonary hypertension
por: Hungerford, Sara Louise, et al.
Publicado: (2023)

Physiology and pathophysiology of prostanoid receptors
por: Narumiya, Shuh
Publicado: (2007)

Right ventricular dysfunction in a hypertensive population stratified by patterns of left ventricular geometry
por: Karaye, Kamilu M, et al.
Publicado: (2012)

Right ventricular assessment in pulmonary hypertension
por: Labrada, Lyana, et al.
Publicado: (2023)

Management of acute subdural hematoma in a patient with portopulmonary hypertension on prostanoid therapy
por: Rammo, Richard, et al.
Publicado: (2017)

Right Ventricular Dysfunction following Acute Myocardial Infarction in the Absence of Pulmonary Hypertension in the Mouse
por: Toldo, Stefano, et al.
Publicado: (2011)

Intravenous sildenafil in right ventricular dysfunction with pulmonary hypertension following a heart transplant
por: Bonet, Luis Almenar, et al.
Publicado: (2014)

Protein Changes Contributing to Right Ventricular Cardiomyocyte Diastolic Dysfunction in Pulmonary Arterial Hypertension
por: Rain, Silvia, et al.
Publicado: (2014)

Pulmonary hypertension, right ventricular dysfunction and acute heart failure: a portentous consortium
por: Michalopoulou, HD, et al.
Publicado: (2015)

Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report
por: McGregor, Pei-Chun, et al.
Publicado: (2021)

Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension
por: Widmann, Laila, et al.
Publicado: (2023)

Diagnostic value of miRNA expression and right ventricular echocardiographic functional parameters for chronic thromboembolic pulmonary hypertension with right ventricular dysfunction and injury
por: Miao, Ran, et al.
Publicado: (2022)

Sex differences in right ventricular function between Groups 1 and 3 pulmonary hypertension
por: Kazmirczak, Felipe, et al.
Publicado: (2023)

Prostanoid Receptors in the Human Vascular Wall
por: Norel, Xavier
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ums8mis34k4m44o2fajogcg6f5